INPROCESS-LSP BV

Their core work

INPROCESS-LSP BV is a Dutch technology SME specializing in inline and online measurement instruments for nanoparticle characterization, with their flagship product being the NanoFlowSizer — a tool for real-time, in-process nanoparticle size measurement. Their core value is enabling pharmaceutical and chemical manufacturers to monitor and control particle properties directly within production lines, eliminating the need for off-line sampling. They apply Process Analytical Technology (PAT) principles to nanomaterial manufacturing, giving quality teams live feedback on particle size distribution during production. Their work sits at the intersection of precision measurement hardware, process control software, and regulatory-compliant pharmaceutical manufacturing.

What they specialise in

How they've shifted over time

INPROCESS-LSP entered H2020 in 2019 with a single-company SME Instrument grant to validate and develop their NanoFlowSizer product — at that stage, the focus was purely on the instrument itself and its market potential, with no keywords attached to the project record. By 2020, they had moved into a collaborative research consortium (PAT4Nano), where their instrument became part of a broader PAT toolbox for nanosuspension manufacturing — a shift from product development to real-world application and validation. The trajectory is clear: they progressed from building the tool to proving it works in industrial manufacturing contexts, which is the natural arc for a deep-tech SME commercializing a measurement instrument.

INPROCESS-LSP is moving from instrument vendor toward embedded process technology partner, making them increasingly relevant to pharmaceutical and chemical manufacturers seeking in-line quality control solutions for nanomaterial production lines.

How they like to work

INPROCESS-LSP has played both roles in EU projects: sole applicant as coordinator on their SME Instrument feasibility study, and partner within a multi-country RIA consortium on PAT4Nano. With only 9 unique partners across 2 projects and 5 countries, their network is focused rather than broad — typical of a technology SME that joins consortia to validate a specific instrument against real industrial use cases rather than to build a large research network. This suggests they are pragmatic collaborators who bring a defined technology asset to a project rather than seeking general research partnerships.

INPROCESS-LSP has collaborated with 9 partners across 5 countries, a compact but genuinely European footprint for a two-project SME. Their network likely spans pharmaceutical manufacturers, academic research groups, and possibly regulatory bodies given the PAT context of their larger project.

What sets them apart

INPROCESS-LSP is one of a very small number of SMEs that have developed a proprietary inline nanoparticle sizing instrument and then validated it within an EU-funded collaborative research program — meaning they bring both a commercial product and peer-reviewed validation to the table. For consortium builders in pharmaceutical manufacturing or nanomedicine, they are a rare combination of technology provider and active research partner rather than just a vendor. Their location in Oss, a major pharmaceutical hub in the Netherlands, further reinforces their relevance to drug formulation and manufacturing consortia.

Highlights from their portfolio

• PAT4Nano
  The largest grant (EUR 1.16M) and longest project, validating NanoFlowSizer technology within a multi-partner European RIA consortium focused on pharmaceutical-grade nanosuspension manufacturing.
• NANOFLOWSIZER
  A coordinator-led SME Instrument Phase 1 project that marks the formal EU-backed launch of their flagship product, signaling commercial readiness and proprietary technology ownership.